FDA Advisory Panel Votes 10-0 for Fast Approval of Seattle Genetics' Hodgkin Drug
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Join SI Premium – FREE
An FDA advisory panel has voted 10-0 for fast approval of Seattle Genetics' (Nasdaq: SGEN) Hodgkin drug.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Gossamer Bio raises up to $250M in private placement for PAH drug
- Hyperfine wins FDA clearance for updated portable MRI software
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
